share_log

Is Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Recent Stock Performance Influenced By Its Financials In Any Way?

Is Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Recent Stock Performance Influenced By Its Financials In Any Way?

是雲南白藥集團有限公司嗎, Ltd(深圳證券交易所股票代碼:000538)最近的股票表現是否受到其財務狀況的影響?
Simply Wall St ·  03/14 00:47

Most readers would already know that Yunnan Baiyao GroupLtd's (SZSE:000538) stock increased by 5.1% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to investigate if the company's decent financials had a hand to play in the recent price move. Specifically, we decided to study Yunnan Baiyao GroupLtd's ROE in this article.

大多數讀者已經知道,雲南白藥集團有限公司(深圳證券交易所代碼:000538)的股票在過去三個月中上漲了5.1%。鑑於股票價格通常與公司的長期財務表現一致,我們決定調查該公司的良好財務狀況是否在近期的價格變動中發揮了作用。具體而言,我們決定在本文中研究雲南白藥集團有限公司的投資回報率。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

股本回報率或投資回報率是股東需要考慮的重要因素,因爲它可以告訴他們資本再投資的有效性。簡而言之,它用於評估公司相對於其股權資本的盈利能力。

How Is ROE Calculated?

ROE 是如何計算的?

Return on equity can be calculated by using the formula:

股本回報率可以使用以下公式計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益

So, based on the above formula, the ROE for Yunnan Baiyao GroupLtd is:

因此,根據上述公式,雲南白藥集團有限公司的投資回報率爲:

12% = CN¥4.8b ÷ CN¥40b (Based on the trailing twelve months to September 2023).

12% = 48億元人民幣 ¥40億元人民幣(基於截至2023年9月的過去十二個月)。

The 'return' is the income the business earned over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.12 in profit.

“回報” 是企業在過去一年中獲得的收入。這意味着,每獲得價值1元人民幣的股東權益,該公司就會產生0.12元人民幣的利潤。

What Is The Relationship Between ROE And Earnings Growth?

投資回報率與收益增長之間有什麼關係?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

到目前爲止,我們已經了解到,投資回報率衡量的是公司創造利潤的效率。現在,我們需要評估公司再投資或 “保留” 了多少利潤以用於未來的增長,從而使我們對公司的增長潛力有所了解。一般而言,在其他條件相同的情況下,股本回報率和利潤留存率高的公司的增長率要高於不具有這些屬性的公司。

Yunnan Baiyao GroupLtd's Earnings Growth And 12% ROE

雲南白藥集團有限公司的收益增長和12%的投資回報率

At first glance, Yunnan Baiyao GroupLtd seems to have a decent ROE. On comparing with the average industry ROE of 8.3% the company's ROE looks pretty remarkable. Needless to say, we are quite surprised to see that Yunnan Baiyao GroupLtd's net income shrunk at a rate of 2.7% over the past five years. We reckon that there could be some other factors at play here that are preventing the company's growth. For example, it could be that the company has a high payout ratio or the business has allocated capital poorly, for instance.

乍一看,雲南白藥集團有限公司的投資回報率似乎不錯。與8.3%的行業平均投資回報率相比,該公司的投資回報率看起來相當可觀。毋庸置疑,我們驚訝地看到,雲南白藥集團有限公司的淨收入在過去五年中以2.7%的速度萎縮。我們認爲,這裏可能還有其他一些因素在起作用,阻礙了公司的發展。例如,可能是該公司的派息率很高,或者企業的資本配置不當。

That being said, we compared Yunnan Baiyao GroupLtd's performance with the industry and were concerned when we found that while the company has shrunk its earnings, the industry has grown its earnings at a rate of 11% in the same 5-year period.

話雖如此,我們將雲南白藥集團有限公司的表現與該行業的表現進行了比較,當我們發現儘管該公司縮減了收益,但該行業在同期5年內以11%的速度增長了收益時,我們對此感到擔憂。

past-earnings-growth
SZSE:000538 Past Earnings Growth March 14th 2024
SZSE: 000538 過去的收益增長 2024 年 3 月 14 日

Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about Yunnan Baiyao GroupLtd's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

收益增長是股票估值的重要因素。對於投資者來說,重要的是要知道市場是否對公司的預期收益增長(或下降)進行了定價。這樣做將幫助他們確定股票的未來是樂觀還是不祥的。如果你想知道雲南白藥集團的估值,可以看看這個衡量其市盈率與行業相比的指標。

Is Yunnan Baiyao GroupLtd Making Efficient Use Of Its Profits?

雲南白藥集團有限公司是否在有效利用其利潤?

Yunnan Baiyao GroupLtd's declining earnings is not surprising given how the company is spending most of its profits in paying dividends, judging by its three-year median payout ratio of 78% (or a retention ratio of 22%). With only a little being reinvested into the business, earnings growth would obviously be low or non-existent.

雲南白藥集團有限公司的收益下降並不奇怪,因爲該公司將大部分利潤用於支付股息,其三年派息率中位數爲78%(或留存率爲22%)。由於只有一小部分被再投資到該業務,收益增長顯然會很低或根本不存在。

Moreover, Yunnan Baiyao GroupLtd has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 73%. As a result, Yunnan Baiyao GroupLtd's ROE is not expected to change by much either, which we inferred from the analyst estimate of 12% for future ROE.

此外,雲南白藥集團有限公司派發股息已有至少十年或更長時間,這表明管理層一定已經意識到股東更喜歡分紅而不是收益增長。我們的最新分析師數據顯示,公司未來三年的派息率預計約爲73%。因此,預計雲南白藥集團有限公司的投資回報率也不會有太大變化,我們從分析師對未來投資回報率爲12%的估計中推斷了這一點。

Summary

摘要

In total, it does look like Yunnan Baiyao GroupLtd has some positive aspects to its business. Yet, the low earnings growth is a bit concerning, especially given that the company has a high rate of return. Investors could have benefitted from the high ROE, had the company been reinvesting more of its earnings. As discussed earlier, the company is retaining a small portion of its profits. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

總的來說,雲南白藥集團有限公司的業務看起來確實有一些積極的方面。但是,低收益增長有點令人擔憂,特別是考慮到該公司的回報率很高。如果該公司將更多的收益再投資,投資者本可以從高投資回報率中受益。如前所述,該公司保留了一小部分利潤。話雖如此,我們研究了分析師的最新預測,發現儘管該公司過去曾縮減收益,但分析師預計其未來收益將增長。這些分析師的預期是基於對該行業的廣泛預期,還是基於公司的基本面?點擊此處進入我們分析師對公司的預測頁面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論